Back to resultsRandomised, Double-blind, Placebo-controlled Study of Topical Clobetasone Butyrate 0.05% Cream in Subjects With Eczema for Two Weeks to Evaluate the Efficacy and Safety
Primary Purpose
Eczema
Status
Completed
Phase
Phase 3
Locations
China
Study Type
Interventional
Intervention
Clobetasone Butyrate 0.05% Cream
Vehicle (base cream)
Sponsored by
About this trial
This is an interventional treatment trial for Eczema focused on measuring eczematous, dermatitis
Eligibility Criteria
Inclusion Criteria:
- Subjects with a diagnosis of eczema, fulfil the 3 follow items: 1) Erythema, papilla/water blister, Lichenification, skin damage with infiltration, 2) unknown reason, recurrent attacks; 3) itching in diseased skin
- Subjects must have body surface area (BSA) disease involvement of less than or equal to 10% as assessed by palm method
- Subject must present with moderate and above eczema as defined by a score greater than or equal to 3 using the investigators global assessment (IGA) of eczema severity.
Exclusion Criteria:
- The subject presents with any systemic disorder or active skin disease (e.g. psoriasis) that would in any way confound interpretation of the study results or subjects who present with scars, moles, tattoos, body piercings, sunburn in the test area which could interfere with the assessment of lesions at screening.
- The subject has eczema restricted to the face, the feet or the hands only.
- The subject is indicated any anti-infectives drug for a current complication of overt bacterial, fungal and viral infection
- History of recent (<1 month) active or presence of current superficial skin infections of viral aetiology such as herpes simplex, or varicella.
- The subject has been exposed to below therapy within the set timeframe: Topical agents administered in the diseased skin, including emollient - 1 week; Systemic administration of anti-histamine agents - 2 week; Systemic administration of corticosteroid -4 week; Systemic administration of immunosuppressive drugs - 4 week; UV therapy -4 week
- Foreseeable intensive ultraviolet (UV) exposure during the study (solar or artificial). Subjects must not be exposed to intense direct sunlight for long periods, and must not use skin tanning devices (e.g. sunbed) for the duration of the study.
- History of clinically significant cardiovascular, pulmonary, gastrointestinal, liver, neurological, renal or haematological abnormalities.
- History of allergy to components of test medications to be used in the study.
- History of anaphylaxis (a sudden, potentially life-threatening systemic allergic reaction) to food, medications, insect venom, or latex.
Sites / Locations
- GSK Investigational Site
- GSK Investigational Site
- GSK Investigational Site
- GSK Investigational Site
- GSK Investigational Site
- GSK Investigational Site
- GSK Investigational Site
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
Other
Arm Label
Clobetasone Butyrate 0.05% Cream
Vehicle (base cream)
Arm Description
Clobetasone Butyrate 0.05% Cream
Vehicle (base cream)
Outcomes
Primary Outcome Measures
Change from baseline in Eczema Area and Severity Index (EASI) score at Day 7
Investigators assessed presence and severity of erythema, induration/papulation, excoriation, and lichenification in four body areas using EASI: head/neck, upper limbs, trunk, and lower limbs. Investigators assigned a severity score from 0 - 3 for each area (none=0, mild=1, moderate=2, and severe=3). Investigators also assigned an area score from 0 (no eruption) to 6 (>90-100% eruption) for each area. The weighting factor was 0.1 for head/neck, 0.2 for upper limbs, 0.3 for trunk, and 0.4 for lower limbs. The total body score for each body region was obtained by multiplying the sum of the severity scores of the four key signs by the area score, then multiplying the result by the constant weighted value assigned to that body region. The sum of these scores gave the EASI total, ranging from 0 to 72. A higher score represented greater disease severity. A negative change from baseline indicates improvement.
Change from baseline in Eczema Area and Severity Index (EASI) score at Day 14
Investigators assessed presence and severity of erythema, induration/papulation, excoriation, and lichenification in four body areas using EASI: head/neck, upper limbs, trunk, and lower limbs. Investigators assigned a severity score from 0 - 3 for each area (none=0, mild=1, moderate=2, and severe=3). Investigators also assigned an area score from 0 (no eruption) to 6 (>90-100% eruption) for each area. The weighting factor was 0.1 for head/neck, 0.2 for upper limbs, 0.3 for trunk, and 0.4 for lower limbs. The total body score for each body region was obtained by multiplying the sum of the severity scores of the four key signs by the area score, then multiplying the result by the constant weighted value assigned to that body region. The sum of these scores gave the EASI total, ranging from 0 to 72. A higher score represented greater disease severity. A negative change from baseline indicates improvement.
Reduction Percentage of Eczema Area and Severity Index (EASI) score after 7 day of treatment
Investigator assessed surface & severity of erythema, induration/papulation, excoriation & lichenification in four body areas using EASI: head/neck, upper extremities, trunk & lower extremities. Investigators assigned a severity score (0-3) for each area (none=0, mild=1, moderate=2, severe=3). Investigators also assigned an area score from 0 (no eruption) to 6 (>90-100% eruption) for each area. Weighting factor was 0.1 for head/neck, 0.2 for upper extremities, 0.3 for trunk & 0.4 for lower extremities. Total body score for each body region was obtained by multiplying sum of severity scores by area score, then multiplying result by constant weighted value assigned to that body region. Sum of these scores gave EASI total, ranging from 0 to 72. Reduction percentage of score was calculated as: (sum of score after day 7 minus sum of score at baseline) *100/sum of score after day 7. Lesser negative reduction percentage lesser severity of disease, more effectiveness of treatment.
Reduction Percentage of Eczema Area and Severity Index (EASI) score after 14 days of treatment
Investigator assessed surface & severity of erythema, induration/papulation, excoriation & lichenification in four body areas using EASI: head/neck, upper extremities, trunk & lower extremities. Investigators assigned a severity score (0-3) for each area (none=0, mild=1, moderate=2, severe=3). Investigators also assigned an area score from 0 (no eruption) to 6 (>90-100% eruption) for each area. Weighting factor was 0.1 for head/neck, 0.2 for upper extremities, 0.3 for trunk & 0.4 for lower extremities. Total body score for each body region was obtained by multiplying sum of severity scores by area score, then multiplying result by constant weighted value assigned to that body region. Sum of these scores gave EASI total, ranging from 0 to 72. Reduction percentage of score was calculated as: (sum of score after day 14 minus sum of score at baseline) *100/sum of score after day 14. Lesser negative reduction percentage lesser severity of disease, more effectiveness of treatment.
Secondary Outcome Measures
Change from baseline in Investigators Global Assessment (IGA) graded score at Day 7 and Day 14
The IGA was used to determine disease severity in a given time and describe severity of eczema using scale of 0 to 6 as follows: 0 Clear:=No inflammatory signs of eczema; 1 Almost clear=Just perceptible erythema and just perceptible papulation/infiltration; 2 Mild:=Mild erythema and mild papulation/infiltration; 3 Moderate:=Moderate erythema, and moderate papulation/infiltration; 4 Severe= Severe erythema, and severe papulation/infiltration; 5 Very Severe=Very severe erythema, and very severe papulation/infiltration with oozing/crusting. Lesser score indicate lesser disease severity.
Changes from baseline in Visual Analog Scale (VAS) at Day 7 and Day 14
Participants assessed the degree of their pruritus using a 100-mm visual analog scale (VAS; 0mm=No itch, 100mm=maximum itch) at Baseline, Day 7 and Day 14. Higher pruritus/itch VAS score indicating more severe pruritus/itching.
Number of participants with participants-based assessment score of disease control at Day 7 and Day 14
The participant's assessment score is a semi-quantitative score intended to reflect the participants own evaluation of disease control. It consisted of a four-point scale ranging from complete disease control (0) to uncontrolled disease (3): 0 - Complete disease control; 1 - Good disease control; 2 - Limited disease control; 3 - Uncontrolled disease. Lesser score indicate better disease control.
Full Information
1. Study Identification
Unique Protocol Identification Number
NCT01567995
Brief Title
Randomised, Double-blind, Placebo-controlled Study of Topical Clobetasone Butyrate 0.05% Cream in Subjects With Eczema for Two Weeks to Evaluate the Efficacy and Safety
Official Title
Randomised, Double-blind, Placebo-controlled Study of Topical Clobetasone Butyrate Cream in Patients With Eczema for Two Weeks to Evaluate the Efficacy and Safety
Study Type
Interventional
2. Study Status
Record Verification Date
November 2017
Overall Recruitment Status
Completed
Study Start Date
February 28, 2008 (Actual)
Primary Completion Date
January 1, 2009 (Actual)
Study Completion Date
February 10, 2009 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
GlaxoSmithKline
4. Oversight
Data Monitoring Committee
No
5. Study Description
Brief Summary
This was a multicenter, randomised, double-blind, two treatment arms, vehicle (cream base) -controlled, parallel-group study in subjects with moderate to severe eczema (defined by investigators global assessment (IGA) score greater than or equal to 3).
Subjects were screened within 3 days prior to randomization. At the screen visit, subjects gave informed consent and were then assessed for health status and eligibility for inclusion in the study. At the baseline visit, subject eligibility was assessed for randomization (Day 0). Eligible subjects were randomised to Clobetasone Butyrate 0.05% Cream group or vehicle (cream base) group at the rate of 1:1. During the treatment phase, subjects returned to the sites in day 7 post-baseline visit for assessment of their disease status and eligibility to continue on the study. During the final visit, 14 days after the baseline, subjects returned to the study sites for assessment of their disease status before completing the study. In addition, the safety and tolerability of Clobetasone Butyrate 0.05% cream were also assessed through the whole trial.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Eczema
Keywords
eczematous, dermatitis
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 3
Interventional Study Model
Parallel Assignment
Masking
ParticipantInvestigator
Allocation
Randomized
Enrollment
240 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Clobetasone Butyrate 0.05% Cream
Arm Type
Experimental
Arm Description
Clobetasone Butyrate 0.05% Cream
Arm Title
Vehicle (base cream)
Arm Type
Other
Arm Description
Vehicle (base cream)
Intervention Type
Drug
Intervention Name(s)
Clobetasone Butyrate 0.05% Cream
Intervention Description
Clobetasone Butyrate 0.05% Cream
Intervention Type
Drug
Intervention Name(s)
Vehicle (base cream)
Intervention Description
Vehicle (base cream)
Primary Outcome Measure Information:
Title
Change from baseline in Eczema Area and Severity Index (EASI) score at Day 7
Description
Investigators assessed presence and severity of erythema, induration/papulation, excoriation, and lichenification in four body areas using EASI: head/neck, upper limbs, trunk, and lower limbs. Investigators assigned a severity score from 0 - 3 for each area (none=0, mild=1, moderate=2, and severe=3). Investigators also assigned an area score from 0 (no eruption) to 6 (>90-100% eruption) for each area. The weighting factor was 0.1 for head/neck, 0.2 for upper limbs, 0.3 for trunk, and 0.4 for lower limbs. The total body score for each body region was obtained by multiplying the sum of the severity scores of the four key signs by the area score, then multiplying the result by the constant weighted value assigned to that body region. The sum of these scores gave the EASI total, ranging from 0 to 72. A higher score represented greater disease severity. A negative change from baseline indicates improvement.
Time Frame
Baseline, Day 7
Title
Change from baseline in Eczema Area and Severity Index (EASI) score at Day 14
Description
Investigators assessed presence and severity of erythema, induration/papulation, excoriation, and lichenification in four body areas using EASI: head/neck, upper limbs, trunk, and lower limbs. Investigators assigned a severity score from 0 - 3 for each area (none=0, mild=1, moderate=2, and severe=3). Investigators also assigned an area score from 0 (no eruption) to 6 (>90-100% eruption) for each area. The weighting factor was 0.1 for head/neck, 0.2 for upper limbs, 0.3 for trunk, and 0.4 for lower limbs. The total body score for each body region was obtained by multiplying the sum of the severity scores of the four key signs by the area score, then multiplying the result by the constant weighted value assigned to that body region. The sum of these scores gave the EASI total, ranging from 0 to 72. A higher score represented greater disease severity. A negative change from baseline indicates improvement.
Time Frame
Baseline, Day 14
Title
Reduction Percentage of Eczema Area and Severity Index (EASI) score after 7 day of treatment
Description
Investigator assessed surface & severity of erythema, induration/papulation, excoriation & lichenification in four body areas using EASI: head/neck, upper extremities, trunk & lower extremities. Investigators assigned a severity score (0-3) for each area (none=0, mild=1, moderate=2, severe=3). Investigators also assigned an area score from 0 (no eruption) to 6 (>90-100% eruption) for each area. Weighting factor was 0.1 for head/neck, 0.2 for upper extremities, 0.3 for trunk & 0.4 for lower extremities. Total body score for each body region was obtained by multiplying sum of severity scores by area score, then multiplying result by constant weighted value assigned to that body region. Sum of these scores gave EASI total, ranging from 0 to 72. Reduction percentage of score was calculated as: (sum of score after day 7 minus sum of score at baseline) *100/sum of score after day 7. Lesser negative reduction percentage lesser severity of disease, more effectiveness of treatment.
Time Frame
up to Day 7
Title
Reduction Percentage of Eczema Area and Severity Index (EASI) score after 14 days of treatment
Description
Investigator assessed surface & severity of erythema, induration/papulation, excoriation & lichenification in four body areas using EASI: head/neck, upper extremities, trunk & lower extremities. Investigators assigned a severity score (0-3) for each area (none=0, mild=1, moderate=2, severe=3). Investigators also assigned an area score from 0 (no eruption) to 6 (>90-100% eruption) for each area. Weighting factor was 0.1 for head/neck, 0.2 for upper extremities, 0.3 for trunk & 0.4 for lower extremities. Total body score for each body region was obtained by multiplying sum of severity scores by area score, then multiplying result by constant weighted value assigned to that body region. Sum of these scores gave EASI total, ranging from 0 to 72. Reduction percentage of score was calculated as: (sum of score after day 14 minus sum of score at baseline) *100/sum of score after day 14. Lesser negative reduction percentage lesser severity of disease, more effectiveness of treatment.
Time Frame
up to Day 14
Secondary Outcome Measure Information:
Title
Change from baseline in Investigators Global Assessment (IGA) graded score at Day 7 and Day 14
Description
The IGA was used to determine disease severity in a given time and describe severity of eczema using scale of 0 to 6 as follows: 0 Clear:=No inflammatory signs of eczema; 1 Almost clear=Just perceptible erythema and just perceptible papulation/infiltration; 2 Mild:=Mild erythema and mild papulation/infiltration; 3 Moderate:=Moderate erythema, and moderate papulation/infiltration; 4 Severe= Severe erythema, and severe papulation/infiltration; 5 Very Severe=Very severe erythema, and very severe papulation/infiltration with oozing/crusting. Lesser score indicate lesser disease severity.
Time Frame
Baseline, Day 7 and Day 14
Title
Changes from baseline in Visual Analog Scale (VAS) at Day 7 and Day 14
Description
Participants assessed the degree of their pruritus using a 100-mm visual analog scale (VAS; 0mm=No itch, 100mm=maximum itch) at Baseline, Day 7 and Day 14. Higher pruritus/itch VAS score indicating more severe pruritus/itching.
Time Frame
Baseline, Day 7 and Day 14
Title
Number of participants with participants-based assessment score of disease control at Day 7 and Day 14
Description
The participant's assessment score is a semi-quantitative score intended to reflect the participants own evaluation of disease control. It consisted of a four-point scale ranging from complete disease control (0) to uncontrolled disease (3): 0 - Complete disease control; 1 - Good disease control; 2 - Limited disease control; 3 - Uncontrolled disease. Lesser score indicate better disease control.
Time Frame
Day 7 and Day 14
10. Eligibility
Sex
All
Minimum Age & Unit of Time
12 Years
Maximum Age & Unit of Time
65 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Subjects with a diagnosis of eczema, fulfil the 3 follow items: 1) Erythema, papilla/water blister, Lichenification, skin damage with infiltration, 2) unknown reason, recurrent attacks; 3) itching in diseased skin
Subjects must have body surface area (BSA) disease involvement of less than or equal to 10% as assessed by palm method
Subject must present with moderate and above eczema as defined by a score greater than or equal to 3 using the investigators global assessment (IGA) of eczema severity.
Exclusion Criteria:
The subject presents with any systemic disorder or active skin disease (e.g. psoriasis) that would in any way confound interpretation of the study results or subjects who present with scars, moles, tattoos, body piercings, sunburn in the test area which could interfere with the assessment of lesions at screening.
The subject has eczema restricted to the face, the feet or the hands only.
The subject is indicated any anti-infectives drug for a current complication of overt bacterial, fungal and viral infection
History of recent (<1 month) active or presence of current superficial skin infections of viral aetiology such as herpes simplex, or varicella.
The subject has been exposed to below therapy within the set timeframe: Topical agents administered in the diseased skin, including emollient - 1 week; Systemic administration of anti-histamine agents - 2 week; Systemic administration of corticosteroid -4 week; Systemic administration of immunosuppressive drugs - 4 week; UV therapy -4 week
Foreseeable intensive ultraviolet (UV) exposure during the study (solar or artificial). Subjects must not be exposed to intense direct sunlight for long periods, and must not use skin tanning devices (e.g. sunbed) for the duration of the study.
History of clinically significant cardiovascular, pulmonary, gastrointestinal, liver, neurological, renal or haematological abnormalities.
History of allergy to components of test medications to be used in the study.
History of anaphylaxis (a sudden, potentially life-threatening systemic allergic reaction) to food, medications, insect venom, or latex.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
GSK Clinical Trials
Organizational Affiliation
GlaxoSmithKline
Official's Role
Study Director
Facility Information:
Facility Name
GSK Investigational Site
City
Nanjing
State/Province
Jiangsu
ZIP/Postal Code
210029
Country
China
Facility Name
GSK Investigational Site
City
Nanjing
State/Province
Jiangsu
ZIP/Postal Code
210042
Country
China
Facility Name
GSK Investigational Site
City
Beijing
ZIP/Postal Code
100034
Country
China
Facility Name
GSK Investigational Site
City
Beijing
ZIP/Postal Code
100044
Country
China
Facility Name
GSK Investigational Site
City
Beijing
ZIP/Postal Code
100730
Country
China
Facility Name
GSK Investigational Site
City
Shanghai
ZIP/Postal Code
200040
Country
China
Facility Name
GSK Investigational Site
City
Tianjin
ZIP/Postal Code
300052
Country
China
12. IPD Sharing Statement
Learn more about this trial
Randomised, Double-blind, Placebo-controlled Study of Topical Clobetasone Butyrate 0.05% Cream in Subjects With Eczema for Two Weeks to Evaluate the Efficacy and Safety
We'll reach out to this number within 24 hrs